Research programme: inflammation and cancer therapeutics - Ampio Pharmaceuticals

Drug Profile

Research programme: inflammation and cancer therapeutics - Ampio Pharmaceuticals

Alternative Names: NCE-001; Para-phenoxy-methylphenidate - Ampio Pharmaceuticals

Latest Information Update: 29 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ampio Pharmaceuticals
  • Developer Ampio Pharmaceuticals; Syngene
  • Class Anti-inflammatories; Antineoplastics; Phenylacetates; Piperazines; Piperidines; Small molecules
  • Mechanism of Action Protein phosphatase 2A stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Glioblastoma; Inflammatory breast cancer; Neuroblastoma; Renal cell carcinoma
  • No development reported Inflammation

Most Recent Events

  • 29 Mar 2018 Preclinical development for Neuroblastoma, Glioblastoma, Renal cell carcinoma, and Inflammatory breast cancer is ongoing in USA
  • 29 Mar 2018 Preclinical trials in Neuroblastoma in USA (unspecified route) before March 2018
  • 16 Jul 2016 No recent reports of development identified for research development in Inflammation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top